Danish University Approves Controversial Hepatitis B Trial in Guinea-Bissau Despite Ethical Protests

Key points

• The University of Southern Denmark approved the trial on October 7, 2026, despite protests from ethics committee members.
• The study will enroll 14,000 infants in Guinea-Bissau, withholding the hepatitis B vaccine from half for the first six weeks of life.
• The US CDC has allocated $1.6 million from global health security funds to support the trial, a move criticized by experts and politicians.
• Critics argue the trial is unethical, comparing it to the Tuskegee experiment, while proponents claim it aligns with current national policy in Guinea-Bissau.
• The trial has faced opposition from the WHO, Africa CDC, and various advocacy groups, with some members of the ethics committee resigning in protest.

Background

This trial follows a series of controversial vaccine policies under the Trump administration, including attempts to split childhood vaccines and reduce immunization schedules. Previous coverage highlighted concerns about the administration's approach to vaccine safety and public health, with some experts warning that such moves could undermine effective disease prevention. The current trial adds to these concerns, particularly given the administration's history of prioritizing political agendas over established medical guidelines.

How outlets are covering it

MS NOW and The Guardian emphasize the ethical concerns and potential harm to infants, drawing parallels to the Tuskegee experiment and highlighting the exploitation of African children. CIDRAP and Rolling Stone focus on the procedural aspects, noting the revised protocol and the role of the CDC in funding the trial. While all sources agree on the controversy, they differ in their emphasis: MS NOW and The Guardian highlight the moral implications, while CIDRAP and Rolling Stone focus on the institutional and procedural failures. The Africa CDC and WHO have expressed significant concerns, but the US CDC and HHS have not responded to inquiries, leaving the official stance unclear.

Why it matters

This trial raises critical questions about the ethics of medical research, particularly in developing countries. It highlights the potential for exploitation of vulnerable populations and the tension between political agendas and public health priorities. The outcome of this trial could set a precedent for future research and influence global health policies, making it a significant issue for public health advocates and policymakers alike.

What to watch

The trial cannot begin until final national authorization is obtained from Guinea-Bissau. Advocacy groups like Stand Up for Science are exploring legal and other actions to prevent the trial from proceeding. The outcome of the Danish Committee on Research Misconduct's review of the researchers' practices may also impact the trial's future. Continued monitoring of the trial's progress and the responses from international health organizations will be crucial in determining its ultimate fate.